{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T11:37:48Z","timestamp":1789558668536,"version":"build-2803163510"},"reference-count":16,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2016,11,22]],"date-time":"2016-11-22T00:00:00Z","timestamp":1479772800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacy Practice"],"published-print":{"date-parts":[[2017,12]]},"abstract":"<jats:p>Sodium\u2013glucose cotransporter 2 (SGLT2) inhibitors have been associated with serious urinary tract infections (UTIs) including pyelonephritis and urosepsis. The Food and Drug Administration (FDA) issued a label change to include this warning in December 2015 due to a small number of cases (n = 19) reported to the FDA Adverse Event Reporting System. Details of these cases are limited and none involved empagliflozin. To date, there has been no published literature comprehensively describing serious UTIs attributed to empagliflozin. We describe a case of septic shock due to Serratia marcescens pyelonephritis and bacteremia that required intensive care unit admission in a well-controlled, type 2 diabetic patient who had begun taking empagliflozin 2 months prior. The patient was treated successfully with intravenous antibiotics followed by oral ciprofloxacin. After discontinuation of empagliflozin and completion of antibiotic therapy, no subsequent UTIs were documented in the following 4 months.<\/jats:p>","DOI":"10.1177\/0897190016679760","type":"journal-article","created":{"date-parts":[[2016,11,22]],"date-time":"2016-11-22T20:57:26Z","timestamp":1479848246000},"page":"672-675","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":9,"title":["A Case of Septic Shock Due to\n                    <i>Serratia marcescens<\/i>\n                    Pyelonephritis and Bacteremia in a Patient Receiving Empagliflozin"],"prefix":"10.1177","volume":"30","author":[{"given":"Wesley D.","family":"Kufel","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Upstate University Hospital, Syracuse, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Scrimenti","sequence":"additional","affiliation":[{"name":"University at Buffalo School of Pharmacy and Pharmaceutical Sciences, Buffalo, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey M.","family":"Steele","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Upstate University Hospital, Syracuse, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2016,11,22]]},"reference":[{"key":"bibr1-0897190016679760","volume-title":"National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014","author":"Centers for Disease Control and Prevention","year":"2014"},{"key":"bibr2-0897190016679760","doi-asserted-by":"crossref","first-page":"84","DOI":"10.4158\/EP161292.PS","volume":"22","author":"Handelsman Y","year":"2016","journal-title":"Endocr Pract"},{"key":"bibr3-0897190016679760","doi-asserted-by":"publisher","DOI":"10.2337\/diaclin.34.1.3"},{"key":"bibr4-0897190016679760","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2012.689956"},{"key":"bibr5-0897190016679760","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12670"},{"key":"bibr6-0897190016679760","unstructured":"Farxiga (dapagliflozin) [package insert]. Wilmington, DE: AstraZeneca; 2015."},{"key":"bibr7-0897190016679760","unstructured":"Jardiance (empagliflozin) [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; 2016."},{"key":"bibr8-0897190016679760","unstructured":"Invokana (canagliflozin) [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc; 2015."},{"key":"bibr9-0897190016679760","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12081"},{"key":"bibr10-0897190016679760","unstructured":"US Food and Drug Administration. FDA Drug Safety Communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm475463.htm. Published January 7, 2016. Accessed June 10, 2016."},{"issue":"7","key":"bibr11-0897190016679760","first-page":"451","volume":"40","author":"Mosley JF","year":"2015","journal-title":"P T"},{"key":"bibr12-0897190016679760","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-159-4-201308200-00007"},{"key":"bibr13-0897190016679760","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2016.03.031"},{"key":"bibr14-0897190016679760","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2015.1100167"},{"key":"bibr15-0897190016679760","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2013.12.052"},{"key":"bibr16-0897190016679760","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2012.06.008"}],"container-title":["Journal of Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0897190016679760","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0897190016679760","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0897190016679760","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:36:41Z","timestamp":1777509401000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0897190016679760"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,22]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["10.1177\/0897190016679760"],"URL":"https:\/\/doi.org\/10.1177\/0897190016679760","relation":{},"ISSN":["0897-1900","1531-1937"],"issn-type":[{"value":"0897-1900","type":"print"},{"value":"1531-1937","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,22]]}}}